Advanced Claudin18.2+ Solid Tumors
Conditions
Interventions
Case series:Treatment by RD07 cell infusion
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years with pathologically/histologically confirmed diagnosis of adenocarcinoma of the stomach or gastroesophageal junction, or pancreatic adenocarcinoma; 2. Must have Claudin18.2+ tumor expression as determined by the Claudin18.2 IHC assay; 3. Failed or been intolerant of prior lines of systemic therapy; 4. Estimated life expectancy > 12 weeks; 5. At least 1 measurable lesion per RECIST 1.1; 6. ECOG performance status of 0~2.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. HBV, HCV, HIV or syphilis infection; 3. Any uncontrolled active infection; 4. Anticancer treatment within 2 weeks prior to leukapheresis; 5. Ever received any treatments targeting Claudin18.2; 6. History of alcoholism, drug abuse or mental illness;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of dose-limiting toxicities (DLTs);Incidence of treatment related adverse events (TRAEs); | — |
Countries
China
Contacts
Public ContactYi Zhang
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed